Pre-earnings options volume in Corcept Therapeutics (CORT) is normal with calls leading puts 10:9. Implied volatility suggests the market is anticipating a move near 3.7%, or $2.71, after results are released. Median move over the past eight quarters is 5.2%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Positive Outlook for Corcept Therapeutics: Buy Rating Backed by Strong Financial Guidance and Pipeline Advancements
- Corcept Therapeutics (CORT) Q1 Earnings Cheat Sheet
- Corcept Therapeutics initiates trial of Phase 2 trial BELLA
- Corcept Therapeutics price target raised to $131 from $128 at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today